{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:06:43Z","timestamp":1785337603364,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Kowa Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12325-021-02023-y","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T12:02:22Z","timestamp":1644667342000},"page":"1659-1677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24\u00a0Months"],"prefix":"10.1007","volume":"39","author":[{"given":"Hidenobu","family":"Tanihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"key":"2023_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137.","journal-title":"Br J Ophthalmol"},{"key":"2023_CR2","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ophtha.2005.05.012","volume":"112","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Iwase A, Araie M, et al. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112:1661\u20139.","journal-title":"Ophthalmology"},{"key":"2023_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.7326\/0003-4819-158-4-201302190-00008","volume":"158","author":"MV Boland","year":"2013","unstructured":"Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2013;158:271\u20139.","journal-title":"Ann Intern Med"},{"key":"2023_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","volume":"377","author":"HA Quigley","year":"2011","unstructured":"Quigley HA. Glaucoma. Lancet. 2011;377:1367\u201377.","journal-title":"Lancet"},{"key":"2023_CR5","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901\u201311.","journal-title":"JAMA"},{"key":"2023_CR6","doi-asserted-by":"publisher","first-page":"6138132","DOI":"10.1155\/2020\/6138132","volume":"2020","author":"B Cvenkel","year":"2020","unstructured":"Cvenkel B, Kolko M. Current medical therapy and future trends in the management of glaucoma treatment. J Ophthalmol. 2020;2020:6138132.","journal-title":"J Ophthalmol"},{"key":"2023_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coph.2012.09.012","volume":"13","author":"C Bucolo","year":"2013","unstructured":"Bucolo C, Salomone S, Drago F, et al. Pharmacological management of ocular hypertension: current approaches and future prospective. Curr Opin Pharmacol. 2013;13:50\u20135.","journal-title":"Curr Opin Pharmacol"},{"key":"2023_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10384-018-0566-9","volume":"62","author":"M Honjo","year":"2018","unstructured":"Honjo M, Tanihara H. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma. Jpn J Ophthalmol. 2018;62:109\u201326.","journal-title":"Jpn J Ophthalmol"},{"key":"2023_CR9","first-page":"137","volume":"42","author":"M Honjo","year":"2001","unstructured":"Honjo M, Tanihara H, Inatani M, et al. Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137\u201344.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2023_CR10","first-page":"1029","volume":"42","author":"PV Rao","year":"2001","unstructured":"Rao PV, Deng P-F, Kumar J, et al. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029\u201337.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2023_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","volume":"126","author":"H Tanihara","year":"2008","unstructured":"Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthal. 2008;126:309\u201315.","journal-title":"Arch Ophthal"},{"key":"2023_CR12","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","volume":"74","author":"KP Garnock-Jones","year":"2014","unstructured":"Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74:2211\u20135.","journal-title":"Drugs"},{"key":"2023_CR13","first-page":"101","volume":"7","author":"M Moshirfar","year":"2018","unstructured":"Moshirfar M, Parker L, Birdsong OC, et al. Use of Rho kinase inhibitors in ophthalmology: a review of the literature. Med Hypothesis Discov Innov Ophthalmol. 2018;7:101\u201311.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"2023_CR14","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1080\/14656566.2017.1378344","volume":"18","author":"T Inoue","year":"2017","unstructured":"Inoue T, Tanihara H. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma. Expert Opin Pharmacother. 2017;18:1669\u201373.","journal-title":"Expert Opin Pharmacother"},{"key":"2023_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12886-020-01490-1","volume":"20","author":"H Tanihara","year":"2020","unstructured":"Tanihara H, Kakuda T, Sano T, et al. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study. BMC Ophthalmol. 2020;20:275.","journal-title":"BMC Ophthalmol"},{"key":"2023_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12325-018-0863-1","volume":"36","author":"H Tanihara","year":"2019","unstructured":"Tanihara H, Kakuda T, Sano T, et al. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 3-month interim analysis of ROCK-J, a post-marketing surveillance study. Adv Ther. 2019;36:333\u201343.","journal-title":"Adv Ther"},{"key":"2023_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10384-013-0284-2","volume":"58","author":"K Kashiwagi","year":"2014","unstructured":"Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol. 2014;58:68\u201374.","journal-title":"Jpn J Ophthalmol"},{"key":"2023_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/112067210501500507","volume":"15","author":"JF Rouland","year":"2005","unstructured":"Rouland JF, Le Pen C, Benhaddi H, et al. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 2 years. Eur J Ophthalmol. 2005;15:562\u201380.","journal-title":"Eur J Ophthalmol"},{"key":"2023_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/112067210801800315","volume":"18","author":"I Goldberg","year":"2008","unstructured":"Goldberg I, Li XY, Selaru P, et al. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2008;18:408\u201316.","journal-title":"Eur J Ophthalmol"},{"key":"2023_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/jop.2008.0072","volume":"25","author":"TJ Zimmerman","year":"2009","unstructured":"Zimmerman TJ, Hahn SR, Gelb L, et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25:145\u201352.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2023_CR21","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamaophthalmol.2014.3333","volume":"132","author":"DK Hwang","year":"2014","unstructured":"Hwang DK, Liu CJ, Pu CY, et al. Persistence of topical glaucoma medication: a nationwide population-based cohort study in Taiwan. JAMA Ophthalmol. 2014;132:1446\u201352.","journal-title":"JAMA Ophthalmol"},{"key":"2023_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/jop.2019.0125","volume":"36","author":"Y Maruyama","year":"2020","unstructured":"Maruyama Y, Ikeda Y, Mori K, et al. Safety and efficacy of long-term ripasudil 0.4% instillation for the reduction of intraocular pressure in Japanese open-angle glaucoma patients. J Ocul Pharmacol Ther. 2020;36:229\u201333.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2023_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IJG.0000000000001203","volume":"28","author":"H Saito","year":"2019","unstructured":"Saito H, Kagami S, Mishima K, et al. Long-term side effects including blepharitis leading to discontinuation of ripasudil. J Glaucoma. 2019;28:289\u201393.","journal-title":"J Glaucoma"},{"key":"2023_CR24","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:e26\u201334.","journal-title":"Acta Ophthalmol"},{"key":"2023_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, et al. Two phase\u00a03 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116\u201327.","journal-title":"Am J Ophthalmol"},{"key":"2023_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","volume":"200","author":"MY Kahook","year":"2019","unstructured":"Kahook MY, Serle JB, Mah FS, et al. Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho kinase elevated IOP treatment trial (ROCKET-2). Am J Ophthalmol. 2019;200:130\u20137.","journal-title":"Am J Ophthalmol"},{"key":"2023_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/bjophthalmol-2019-315776","volume":"105","author":"Y Maruyama","year":"2021","unstructured":"Maruyama Y, Ikeda Y, Mori K, et al. Morphological change and recovery of corneal endothelial cells after rho-associated protein kinase inhibitor eye-drop (ripasudil 0.4%) instillation. Br J Ophthalmol. 2021;105:169\u201373.","journal-title":"Br J Ophthalmol"},{"key":"2023_CR28","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1167\/iovs.15-17887","volume":"56","author":"N Okumura","year":"2015","unstructured":"Okumura N, Okazaki Y, Inoue R, et al. Rho-associated kinase inhibitor eye drop (ripasudil) transiently alters the morphology of corneal endothelial cells. Invest Ophthalmol Vis Sci. 2015;56:7560\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2023_CR29","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","volume":"131","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131:1288\u201395.","journal-title":"JAMA Ophthalmol"},{"key":"2023_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731-6 e2.","journal-title":"Am J Ophthalmol"},{"key":"2023_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ajo.2020.12.006","volume":"224","author":"U Schl\u00f6tzer-Schrehardt","year":"2021","unstructured":"Schl\u00f6tzer-Schrehardt U, Zenkel M, Strunz M, et al. Potential functional restoration of corneal endothelial cells in fuchs endothelial corneal dystrophy by ROCK inhibitor (ripasudil). Am J Ophthalmol. 2021;224:185\u201399.","journal-title":"Am J Ophthalmol"},{"key":"2023_CR32","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMoa1712770","volume":"378","author":"S Kinoshita","year":"2018","unstructured":"Kinoshita S, Koizumi N, Ueno M, et al. Injection of cultured cells with a ROCK inhibitor for bullous keratopathy. N Engl J Med. 2018;378:995\u20131003.","journal-title":"N Engl J Med"},{"key":"2023_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","volume":"133","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133:755\u201361.","journal-title":"JAMA Ophthalmol"},{"key":"2023_CR34","doi-asserted-by":"publisher","first-page":"10308","DOI":"10.1038\/s41598-020-66928-4","volume":"10","author":"A Futakuchi","year":"2020","unstructured":"Futakuchi A, Morimoto T, Ikeda Y, et al. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study. Sci Rep. 2020;10:10308.","journal-title":"Sci Rep"},{"key":"2023_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00417-018-3933-9","volume":"256","author":"S Kusuhara","year":"2018","unstructured":"Kusuhara S, Katsuyama A, Matsumiya W, et al. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2018;256:809\u201314.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2023_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40261-017-0509-0","volume":"37","author":"R Matsumura","year":"2017","unstructured":"Matsumura R, Inoue T, Matsumura A, et al. Efficacy of ripasudil as a second-line medication in addition to a prostaglandin analog in patients with exfoliation glaucoma: a pilot study. Clin Drug Investig. 2017;37:535\u20139.","journal-title":"Clin Drug Investig"},{"key":"2023_CR37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000431196","volume":"55","author":"SJ Havens","year":"2016","unstructured":"Havens SJ, Gulati V. Neovascular glaucoma. Dev Ophthalmol. 2016;55:196\u2013204.","journal-title":"Dev Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-02023-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-02023-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-02023-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T11:40:27Z","timestamp":1649331627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-02023-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-02023-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}